4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeAdvanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast CarcinomaRecruitingPhase 22026-07-30NCT06486883
Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate CancerGenital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderNot yet recruitingPhase 22026-07-21NCT07717099
Sacituzumab Govitecan in Primary HER2-negative Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinomaActive, not recruitingPhase 32026-04-22NCT04595565
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficienciesEnrolling by invitationPhase 32026-04-17NCT05667493